2018 Large Cap Biopharmaceutical Stocks : First Quarter Performance Update

http://oceanadesigns.net/envira/azul-aran/ 2018 Large Cap Biopharmaceuticals – Performance Compared to ETFs

It has been a rough start for large cap biopharmaceutical stocks but the ETFs (FBT) and (XBI) still outperformed the SPY YTD and over 12 months. Most Individual stocks lagged unless you owned click here Abbvie (ABBV) or Vertex Pharmaceuticals (VRTX). Here are some key takeaways:

  • Buy the worst performers on technicals and valuations? BIIB CELG REGN.
  • Look at most stable stocks with good performance and dividends: BMY GILD.
  • Fidelity biotechnology fund (FBIOX) is outperforming the large cap weighted (IBB).
  • Over 12 months the FBT and XBI are the top performing ETFs.
  • Double bottom in key indices after Q1 could be a  buy signal.
Ticker Price 2017 Market P/S % Perform % Perform
3/30/2018 Rev$B Cap $B 12 mos YTD 2018 YTD
3/30/2018
see url Abbvie ABBV 94.65 28.22 151.29 5.36 43.9 -2.13
Alexion ALXN 111.46 3.55 25.48 7.17 -7.67 -6.8
Amgen AMGN 170.48 22.85 127.66 5.59 4.55 -1.97
Biogen BIIB 273.82 12.27 60.55 4.93 1.97 -14
Bristol MyersSquibb BMY 63.25 20.78 106.41 5.12 14.2 3.16
Celgene CELG 89.21 13 68.63 5.28 -28.7 -14.5
Gilead Sci GILD 75.39 26.11 102.46 3.92 12.09 5.23
Merck MRK 54.47 40.12 148.81 3.71 -2.1 -13.4
Regeneron REGN 344.36 5.87 37.82 6.44 -12.6 -8.41
Vertex VRTX 162.98 2.49 42.71 17.16 50.9 8.79
XBI 87.73 25.8 3.37
FBT  132.9 26.5 6.69
IBB 106.74 8.76 0
FBIOX 226.14 11.7 3.07
XLV 81.4 9.17 -1.55

 

 

No comments yet.

Leave a Reply